Smoking but not homozygosity for CYP1A2 g-163A allelic variant leads to earlier disease onset in patients with sporadic porphyria cutanea tarda

Antonio Fontanellas*, Maria Martinez-Fresno, Maria Concepcion Garrido-Astray, Teresa Perucho, Maria-Josefa Moran-Jimenez, Maria Garcia-Bravo, Manuel Mendez, Pamela Poblete-Gutierrez, Jorge Frank, Nuno Henriques-Gil, Rafael Enriquez de Salamanca

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Web of Science)

Abstract

Porphyria cutanea tarda (PCT) results from decreased activity of hepatic uroporphyrinogen decarboxylase (UROD). Both sporadic and familial forms are characterised by typical cutaneous lesions triggered by genetic/environmental factors. Studies in rodents showed that cytochrome P4501A2 (CYP1A2) plays a central role in the synthesis of a competitive inhibitor of hepatic UROD, but there is little evidence in humans. The impact of smoking and CYP1A2 g-163C > A allelic variant upon first appearance of clinical signs was investigated in 102 patients (80 sporadic-PCT) and 150 healthy donors from Spain. We found an increase in the frequency of CYP1A2 g-163A allele in patients with PCT when compared with controls, although the more inducible A/A genotype had no effect on the onset age. In sporadic-PCT, smoking leads to earlier onset of clinically overt disease in moderate-to-heavy smokers (>= 10 cigarettes/day). In conclusion, this study provides evidence that smoking hastens the onset of cutaneous symptoms in sporadic-PCT patients.
Original languageEnglish
Pages (from-to)E326-E328
JournalExperimental Dermatology
Volume19
Issue number8
DOIs
Publication statusPublished - Aug 2010

Keywords

  • cytochrome P4501A2 allelic variant
  • onset of cutaneous symptoms
  • porphyria
  • tobacco smoke
  • uroporphyrinogen decarboxylase

Cite this